FDA approves UCB drug for Parkinson's, restless legs syndrome

Agency gives approval to Neupro patch

ATLANTA — The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.

UCB announced the FDA approval of Neupro (rotigotine) transdermal system advanced-stage idiopathic Parkinson's and moderate-to-severe restless legs syndrome.

"Neupro represents an innovation in the treatment of Parkinson's disease and restless legs syndrome," UCB chief medical officer and EVP global projects and development Iris Loew-Friedrich said. "UCB is thrilled to make Neupro available to patients living with these serious diseases."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.